Hospital Alemao Oswaldo Cruz | Centro Internacional de Pesquisa

Research site

(Unclaimed)

Location

Rua Joao Juliao, 331, Sao Paulo, Sao Paulo, Brazil

Site insights

Top conditions

Top treatments

Atezolizumab

Prednisone

BI 1015550

Vincristine

Cyclophosphamide

Milvexian

Apixaban

Prednisone Versus Abiraterone Acetate

Abiraterone Acetate

Niraparib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

18 of 33 total trials

A Follow-up Study to Test Long-term Treatment With BI 1015550 in People With Pulmonary Fibrosis Who Took Part in a Previous Study With BI 1015550 (FIBRONEER™-ON)

This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have c...

Enrolling

Progressive Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

Drug: BI 1015550

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

This study will evaluate the efficacy, safety, and pharmacokinetics of tobemstomig alone or in combination with tiragolumab compared with atezolizuma...

Enrolling

Urothelial Cancer

Drug: Tiragolumab

Drug: Atezolizumab

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma (Celestimo)

This study will evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M + Len) compared to rituximab in combination wit...

Enrolling

Relapsed or Refractory Follicular Lymphoma

Drug: Lenalidomide

Drug: Rituximab

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PRIMORDIUM)

The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist...

Active, not recruiting

Prostatic Neoplasms

Radiation: Radiotherapy

Drug: LHRHa

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2)

The purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) a...

Active, not recruiting

Carcinoma, Non-Small-Cell Lung

Drug: Pemetrexed

Drug: Carboplatin

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PALOMA-2)

The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombin...

Enrolling

Carcinoma, Non-small-Cell Lung

Drug: Lazertinib

Drug: Direct Oral Anticoagulant (DOAC)

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling

Acute Coronary Syndrome

Drug: Milvexian

Other: Placebo

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

Enrolling

Ischemic Stroke; Ischemic Attack, Transient

Drug: Placebo

Drug: Milvexian

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (LIBREXIA-AF)

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Enrolling

Atrial Fibrillation

Drug: Apixaban Placebo

Drug: Milvexian

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE)

The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus predniso...

Active, not recruiting

Metastatic Castration-sensitive Prostate Cancer

Drug: Niraparib

Drug: Prednisone

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE)

The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP...

Active, not recruiting

Castration-Resistant Prostatic Cancer

Drug: Prednisone

Drug: New Formulation of Niraparib and Abiraterone Acetate (AA)

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (SunRISe-2)

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV)...

Active, not recruiting

Urinary Bladder Neoplasms

Drug: Cisplatin

Radiation: Hypo-fractioned radiation therapy

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP)

Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer.BCR means that in men who had p...

Enrolling

Biochemically Recurrent Prostate Cancer

Other: Placebo matching darolutamide

Drug: Darolutamide (BAY1841788, Nubeqa)

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of t...

Enrolling

Diffuse Large B-Cell Lymphoma

Drug: Epcoritamab

Drug: Cyclophosphamide

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma (GLOBRYTE)

The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus benda...

Enrolling

Lymphoma

Drug: Glofitamab

Drug: Rituximab

A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous Nephropathy

The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to e...

Enrolling

Primary Membranous Nephropathy

Drug: Tacrolimus

Drug: Zanubrutinib

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

This study is open to adults with a lung disease called Idiopathic Pulmonary Fibrosis (IPF). People can join the study if they are 40 years or older....

Active, not recruiting

Idiopathic Pulmonary Fibrosis

Drug: Placebo

Drug: BI 1015550

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic...

Active, not recruiting

Lung Diseases, Interstitial

Drug: BI 1015550

Drug: Placebo